Select Medical Holdings Corp (SEM) Q4 2025 Earnings Call Transcript

Why It Matters

The take‑private discussion could reshape ownership and capital structure, while the earnings mix signals pressure on outpatient profitability that investors must monitor.

Key Takeaways

• Board reviewing nonbinding take‑private offer
• Q4 revenue up >6% across all divisions
• Adjusted EBITDA fell 10% to $104.7M
• Outpatient margin slipped to 3.4% after discounts
• 2026 guidance targets $5.6‑$5.8B revenue

Pulse Analysis

Select Medical’s earnings call highlighted a pivotal governance moment: the Board’s special committee is weighing a non‑binding offer from the Executive Chairman to acquire all outstanding shares. Such a take‑private scenario often triggers valuation reassessments and could unlock strategic flexibility, but it also introduces uncertainty for shareholders awaiting clarity on pricing, timing, and potential debt restructuring. Analysts will be watching how the proposal aligns with the company’s growth trajectory and existing capital commitments, especially given its sizable $1.8 billion debt load and limited cash reserves.

Financially, the quarter delivered a mixed picture. Revenue growth exceeded 6% across inpatient rehab, critical‑illness recovery, and outpatient divisions, underscoring the effectiveness of recent bed‑additions and partnership expansions with Cleveland Clinic and Vibra Healthcare. However, adjusted EBITDA contracted 10% to $104.7 million, primarily because of a $15 million health‑insurance expense surge and $6 million in variable discounts that hit the outpatient segment hardest. The outpatient rehab division’s margin slipped to 3.4% as Medicare reimbursement rates softened and payer‑mix dynamics shifted toward higher‑cost managed Medicare patients. A modest 2% Medicare rate increase slated for 2026 offers a potential upside, but the company must still address cost‑inflation and staffing challenges.

Looking ahead, Select Medical’s 2026 guidance anticipates $5.6‑$5.8 billion in revenue and $520‑$540 million in adjusted EBITDA, predicated on improved outpatient margins and continued inpatient rehab expansion. The firm plans to add 399 rehab beds through 2027, reinforcing its market position in high‑margin inpatient services. Capital allocation will feature a $0.0625 per‑share dividend and ongoing investments in AI‑driven billing processes, aiming to offset margin erosion. Investors should weigh the upside of the expansion pipeline against the risks posed by outpatient softness, debt leverage, and the unresolved take‑private transaction.